19 hours ago
1
JHVEPhoto/iStock Editorial via Getty Images
Novo Nordisk (NVO) continued its downward spiral and fell 3.8% in premarket trade, a day after the Danish drugmaker slashed its full-year outlook, weighed down by its obesity drug franchise led by its GLP-1 medication semaglutide.
The decline on Tuesday
English (US) ·